BL
DXCM icon

Balentine LLC’s DexCom DXCM Stock Holding History

Balentine LLC’s Portfolio DXCM Stock Details DXCM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-5,369
Closed -$745K – 293
2024
Q1 		$745K Buy
5,369
+551
+11% +$69.3K 0.02% 229
2023
Q4 		$598K Buy
+4,818
New +$492K 0.02% 248
2023
Q3 		– Sell
-1,937
Closed -$249K – 571
2023
Q2 		$249K Buy
+1,937
New +$234K 0.01% 431
2020
Q3 		– Sell
-664
Closed -$67K – 347
2020
Q2 		$67K Buy
664
+32
+5% +$2.86K ﹤0.01% 199
2020
Q1 		$43K Buy
632
+156
+33% +$9.71K ﹤0.01% 193
2019
Q4 		$26K Buy
+476
New +$22.6K ﹤0.01% 275
2017
Q3 		– Sell
-460
Closed -$8.13K – 650
2017
Q2 		$8K Buy
460
+104
+29% +$1.92K ﹤0.01% 461
2017
Q1 		$8K Sell
356
-28
-7% -$547 ﹤0.01% 434
2016
Q4 		$6K Buy
384
+60
+19% +$1.06K ﹤0.01% 441
2016
Q3 		$7K Sell
324
-4
-1% -$89 ﹤0.01% 389
2016
Q2 		$7K Buy
+328
New +$5.58K ﹤0.01% 381

Other funds holding DXCM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Balentine LLC's DXCM Position: Q2 2024 in Review

Balentine LLC sold out of DexCom (DXCM) in Q2 2024, closing a stake of 5,369 shares — an estimated $745K sold.

Balentine LLC first reported a position in DXCM in Q2 2016 and held it in 11 quarters. The position peaked at $745K in Q1 2024. 1,000 funds tracked by Wall St. Rank hold DXCM as of Q2 2024.

  • Balentine LLC reported no remaining DexCom position as of Q2 2024 after selling out during the quarter.
  • Balentine LLC sold 5,369 DexCom shares in Q2 2024, an estimated $745K.
  • Balentine LLC first reported a position in DexCom in Q2 2016 and held it in 11 quarters.
  • Balentine LLC's DexCom position peaked at $745K in Q1 2024.
  • 1,000 funds tracked by Wall St. Rank held DexCom as of Q2 2024.

Based on Balentine LLC's 13F filing for Q2 2024, filed 7 Aug 2024.